

Veldoreotide

Cat. No.:	HY-P0024
CAS No.:	252845-37-7
Molecular Formula:	C ₆₀ H ₇₄ N ₁₂ O ₁₀
Molecular Weight:	1123.3
Target:	Somatostatin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent ^[1]										
IC₅₀ & Target	SSTR2 37.6 nM (EC50)	SSTR3 31.3 nM (EC50)	SSTR4 10.5 nM (EC50)								
In Vitro	<p>Veldoreotide stimulates the SST2, SST4, and SST5 receptors with high potency and efficacy in the HEK293 cells, co-expressing these receptors with the GIRK2 channels; EC₅₀s of 37.6 ± 4.5 nM, 31.3 ± 14.4 nM and 10.5 ± 3.4 nM for GIRK2-SST2, GIRK2-SST4 and GIRK2-SST5, respectively^[1].</p> <p>Veldoreotide (10 µM; 24 h) inhibits SST4-expressing BON-1 cells^[1].</p> <p>Veldoreotide (DG3173) (100 nM or 1 µM; 6 h) inhibits GH secretion in adenomas with an IC₅₀ of 0.49 nM^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>SST4-expressing BON-1 cells</td> </tr> <tr> <td>Concentration:</td> <td>10 µM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited SST4-expressing BON-1 cells, while did not significantly inhibited wild type BON-1 cells.</td> </tr> </table>			Cell Line:	SST4-expressing BON-1 cells	Concentration:	10 µM	Incubation Time:	24 h	Result:	Inhibited SST4-expressing BON-1 cells, while did not significantly inhibited wild type BON-1 cells.
Cell Line:	SST4-expressing BON-1 cells										
Concentration:	10 µM										
Incubation Time:	24 h										
Result:	Inhibited SST4-expressing BON-1 cells, while did not significantly inhibited wild type BON-1 cells.										

REFERENCES

- [1]. Dasgupta P, et al. Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. *Life* (Basel). 2021 Oct 12;11(10):1075.
- [2]. Plöckinger U, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. *Eur J Endocrinol*. 2012 Feb;166(2):223-34.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA